DTL
ABOS icon

Dynamic Technology Lab’s Acumen Pharmaceuticals ABOS Stock Holding History

Dynamic Technology Lab’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,525
Closed -$57K – 1029
2022
Q4 		$57K Buy
+10,525
New +$70.7K 0.01% 1021

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Dynamic Technology Lab's ABOS Position: Q1 2023 in Review

Dynamic Technology Lab sold out of Acumen Pharmaceuticals (ABOS) in Q1 2023, closing a stake of 10,525 shares — an estimated $57K sold.

Dynamic Technology Lab first reported a position in ABOS in Q4 2022 and held it in 1 quarter. The position peaked at $57K in Q4 2022. 61 funds tracked by Wall St. Rank hold ABOS as of Q1 2023.

  • Dynamic Technology Lab reported no remaining Acumen Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Dynamic Technology Lab sold 10,525 Acumen Pharmaceuticals shares in Q1 2023, an estimated $57K.
  • Dynamic Technology Lab first reported a position in Acumen Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Dynamic Technology Lab's Acumen Pharmaceuticals position peaked at $57K in Q4 2022.
  • 61 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2023.

Based on Dynamic Technology Lab's 13F filing for Q1 2023, filed 12 May 2023.